Mass General Brigham

CodaMetrix Announces $40M Series B Financing to Advance Medical Coding Quality and Clinically Enrich Claims Data Through AI

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Data Management, Technology, Artificial Intelligence, Organization, Mass General Brigham, Entrepreneurship, Partner (business rank), Acceleration, Artificial intelligence, GI, Radiology, University, Pathology, Mount Sinai Health System, Mass, Emerge Commerce, Medical device

Transformation Capital led the financing with continued support from existing investors SignalFire, Series A lead, and Frist Cressey Ventures.

Key Points: 
  • Transformation Capital led the financing with continued support from existing investors SignalFire, Series A lead, and Frist Cressey Ventures.
  • Series B financing will be used to further advance CodaMetrix’s AI-powered solutions which improve medical coding quality, produce clinically comprehensive data sets, reduce the overall cost of care, and alleviate administrative burden on providers.
  • “Medical coding is one of the most time-consuming, understaffed and inherently error-prone parts of the health system revenue cycle.
  • “Our game changing AI platform delivers vital automation which not only addresses these pain points but, more significantly, changes claims data from notoriously unreliable to clinically valuable.

Behavioral Health Industry Experts Join Oceans Healthcare's Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Acumen, Harvard Medical School, Child and adolescent psychiatry, Partner, Psychiatry, Communication, Massachusetts General Hospital, Partnership, COVID-19, Patient, Mass General Brigham, Knowledge, Child, Human services, Adolescence, Pediatrics, Medicaid, Hospital, Medicare, Policy, Legislation, Nursing

PLANO, Texas, March 21, 2024 /PRNewswire/ -- Oceans Healthcare has announced the addition of highly regarded Harvard Medical School psychiatry professor Dr. Michael Jellinek and decorated public health executive Dr. Courtney Phillips to its Board of Directors. These additions underscore the growing behavioral health organization's commitment to advancing healing and long-term recovery through patient-centered behavioral health care.

Key Points: 
  • These additions underscore the growing behavioral health organization's commitment to advancing healing and long-term recovery through patient-centered behavioral health care.
  • "Our nation's behavioral health crisis demands leaders with a breadth of knowledge and unwavering compassion," said Oceans Healthcare CEO Stuart Archer.
  • "Effective communication, alongside advocating for legislation that supports patients and health care providers, is crucial in informing stakeholders about the intricate nature and continuum of behavioral health services," Phillips emphasized.
  • Through acquisitions, high-profile joint ventures, new facility development and the addition of new services, Oceans has grown 300% since 2014.

Microsoft and NVIDIA announce major integrations to accelerate generative AI for enterprises everywhere

Retrieved on: 
Monday, March 18, 2024
Cloud, Microsoft, Sanofi, Microsoft Azure, GTC, Organization, Natural language processing, GPU, Triton, Broad Institute, Public health, Biotechnology, Mass General Brigham, MIT, InfiniBand, Harvard University, SAN, MIG, 3D, Microsoft Power BI, AI, University, First officer (aviation), Software, GENETICS, AUC, VM, LLM, Cloud computing, VMS, Creativity, NIM, Flywheel, NVIDIA, Health, Mass, Silicon, Video game

New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI

Key Points: 
  • New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI
    REDMOND, Wash. and SAN JOSE, Calif., March 18, 2024 /PRNewswire/ -- At GTC on Monday, Microsoft Corp. and NVIDIA expanded their longstanding collaboration with powerful new integrations that leverage the latest NVIDIA generative AI and Omniverse™ technologies across Microsoft Azure, Azure AI services, Microsoft Fabric and Microsoft 365.
  • "AI is transforming our daily lives — opening up a world of new opportunities," said Jensen Huang, founder and CEO of NVIDIA.
  • At NVIDIA GTC , Microsoft is demonstrating a preview of what is possible using Omniverse Cloud APIs on Microsoft Azure.
  • NVIDIA GPUs and NVIDIA Triton Inference Server™ help serve AI inference predictions in Microsoft Copilot for Microsoft 365.

New consortium of healthcare leaders announces formation of Trustworthy & Responsible AI Network (TRAIN), making safe and fair AI accessible to every healthcare organization

Retrieved on: 
Monday, March 11, 2024
Informatics, Algorithm, Responsibility, Information technology, Health, Biomedical Research, Patient, Cleveland Clinic, Approximation error, Artificial intelligence in healthcare, Microsoft, Public, AdventHealth, Mass General Brigham, Coalition, Science, Policy, Safety, Boston Children's Hospital, VUMC, Organization, Bias, Trust (social science), Research, AI, University, Nouvelle AI, MPH, Vanderbilt University Medical Center, Hospital, Sharp HealthCare, Internal medicine, Health informatics, Conference, Public health, Cardiology, Caregiver, MedStar Health, CHAI, HIMSS, Mount Sinai Health System, Medical device

New AI capabilities have the potential to transform the healthcare industry by enabling better care outcomes, improving efficiency and productivity, and reducing costs.

Key Points: 
  • New AI capabilities have the potential to transform the healthcare industry by enabling better care outcomes, improving efficiency and productivity, and reducing costs.
  • Enabling registration of AI used for clinical care or clinical operations through a secure online portal.
  • "By working together, TRAIN members aim to establish best practices for operationalizing responsible AI, helping improve patient outcomes and safety while fostering trust in healthcare AI."
  • "We are excited to join our TRAIN partners in the journey to accelerate AI innovation in an ethical, responsible and safe way."

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

Retrieved on: 
Tuesday, March 5, 2024
Mass, Mass General Brigham, DSM-IV codes, FDA, Hospital, Bleeding, Edema, Conference, Protein, Microglia, Research, Human, Pharmaceutical industry

AD/PD is the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal.

Key Points: 
  • AD/PD is the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal.
  • Our research has demonstrated that intranasal rodent anti-CD3 mAb and intranasal fully human anti-CD3 mAb (foralumab) will decrease microglia activation in rodents and humans, respectively.
  • Nasal anti-CD3 has also shown to reduce hemorrhage and edema that occurs with ARIA.”
    “With the focus on effective Alzheimer’s disease treatments and we have the potential to be a novel, first in class neuroinflammatory modulator,” commented Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences.
  • The data also excitingly shows a reduction of hemorrhage and edema that occurs with ARIA.”

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

Retrieved on: 
Monday, February 26, 2024
Science, Neurology, Biometrics, Biotechnology, Research, General Health, Health, Health Technology, Mass, Mass General Brigham, Hospital, AdventHealth, Alzheimer's disease, Doctor of Philosophy, Medical school, MD, Physician, Quality of life, UPMC, Biomarker, Mayo Clinic, Patient, CSF, Disease, Diagnosis, Plasma, Harvard Medical School, Corporation, Workflow, Medical imaging

These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.

Key Points: 
  • These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.
  • This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.
  • Traditional AD diagnosis has relied on combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD.
  • “In our pursuit to build the global testing infrastructure for Alzheimer’s disease, Quanterix is pleased to work with several health systems whose combined networks treat millions of patients,” said Masoud Toloue, CEO of Quanterix.

DR. THOMAS H. LEE ELECTED TO BLUE CROSS BLUE SHIELD OF MASSACHUSETTS BOARD OF DIRECTORS

Retrieved on: 
Wednesday, February 7, 2024
Blue Cross, Press Ganey Associates, Mass General Brigham, Mass, Woman, Organization, Health insurance

BOSTON, Feb. 7, 2024 /PRNewswire/ -- Dr. Thomas H. Lee, one of the country's leading health policy experts, has been elected to the Blue Cross Blue Shield of Massachusetts (Blue Cross) board of directors. A cardiologist who has long focused on improving the quality and efficiency of health care, he is currently chief medical officer at Press Ganey, the health care performance improvement consulting firm.

Key Points: 
  • BOSTON, Feb. 7, 2024 /PRNewswire/ -- Dr. Thomas H. Lee, one of the country's leading health policy experts, has been elected to the Blue Cross Blue Shield of Massachusetts (Blue Cross) board of directors.
  • "Tom will provide our board with the clinical perspective he's honed over 30 years," said board Chair Dorothy Puhy.
  • "I'm pleased to join the board of Blue Cross Blue Shield of Massachusetts and help it continue to innovate in ways that advance access to quality and affordable health care for all," said Lee.
  • Lee will serve on the board's finance and business performance committee and the health care quality and affordability committee.

Astellas Announces Strategic Collaboration with Mass General Brigham

Retrieved on: 
Tuesday, January 30, 2024
Research, MD, Patient, Biomedical Research, AUC, Mass General Brigham, Gene, Mass, Pharmaceutical industry

TOKYO, Jan. 30, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today that it has entered into a strategic collaboration with Mass General Brigham (President and CEO: Anne Klibanski, MD) that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise.

Key Points: 
  • TOKYO, Jan. 30, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today that it has entered into a strategic collaboration with Mass General Brigham (President and CEO: Anne Klibanski, MD) that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise.
  • Through the alliance, Astellas and Mass General Brigham aim to:
    Accelerate innovation through collaborative research, as well as exploring and expanding new research frontiers.
  • Located in Boston, Massachusetts, Mass General Brigham is one of the leading academic medical centers in the United States.
  • "We are incredibly excited about this collaboration with Mass General Brigham – one of the leading biomedical research organizations in the U.S. – and the promise it represents.

Calling all MedTech innovators: Up to $100,000 in federal grants to be awarded

Retrieved on: 
Monday, January 29, 2024
Research, Tufts Medical Center, Emergency, Health equity, Johns Hopkins University, PPN, Disaster, HRSA, MBA, Pandemic, Food, Microsoft, Human services, Mass, Organization, Marketing, Doctor of Philosophy, Small business, Mass General Brigham, Resource, Pharmaceutical industry

MCMs play a pivotal role in bolstering readiness and response capabilities to disasters arising from a broad spectrum of threats.

Key Points: 
  • MCMs play a pivotal role in bolstering readiness and response capabilities to disasters arising from a broad spectrum of threats.
  • An additional incentive is the potential for a second year of funding, based on the awardees’ progress in the first year.
  • Organizers are particularly interested in funding research and development (R&D) initiatives focused on pioneering early-stage medical technologies tailored to tackle disasters.
  • Such initiatives also have the potential to secure subsequent funding from other federal agencies operating within this domain.

Draganfly Announces Agreement to Pilot Drone Delivery Services Program for Mass General Brigham’s Home Hospital

Retrieved on: 
Tuesday, January 16, 2024
Patient, Research, Health, Home, Lafayette Home Hospital, Massachusetts General Hospital, Map, Hospital, Mass, Mass General Brigham

Boston, MA., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce an agreement with Mass General Brigham to provide drone delivery and solutions for the healthcare system’s Home Hospital patients. Home Hospital aims to create a model that enhances the overall patient experience, improves access to essential services, and provides more cost-effective solutions for its patients.

Key Points: 
  • Boston, MA., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce an agreement with Mass General Brigham to provide drone delivery and solutions for the healthcare system’s Home Hospital patients.
  • Home Hospital aims to create a model that enhances the overall patient experience, improves access to essential services, and provides more cost-effective solutions for its patients.
  • Mass General Brigham’s Home Hospital is one of the largest in the country.
  • Draganfly’s drone technology and pilot services will map and develop delivery routes to support the needs of both patients and staff.